ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
Dow Jones
44.296,51
0,97%
Euro vs US Dollar
1,0418
0,00%
Bitcoin
98.066,35
0,29%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) News

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SNPX
DatumZeitQuelleÜberschriftSymbolFirma
12/11/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/11/202414h54Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
05/11/202412h01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
28/10/202421h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
22/10/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNPXSynaptogenix Inc
10/10/202423h11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SNPXSynaptogenix Inc
04/10/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
23/09/202423h04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SNPXSynaptogenix Inc
13/09/202422h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
11/09/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
11/09/202415h00PR Newswire (US)Synaptogenix Announces $5.0 Million FinancingNASDAQ:SNPXSynaptogenix Inc
09/09/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
14/08/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
18/07/202415h00PR Newswire (US)Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryNASDAQ:SNPXSynaptogenix Inc
26/06/202415h00PR Newswire (US)Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
15/05/202423h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202415h00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202415h15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202415h15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202414h00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202416h16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
21/12/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
19/12/202315h00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202315h00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
14/11/202323h05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
13/11/202323h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
06/11/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
03/11/202322h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
02/11/202314h00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202315h00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNPX

Kürzlich von Ihnen besucht

NYSE
DIS
Walt Disney
TG
TUI1
Tui
TG
BAYN
Bayer
DBI
DAX
DAX
CCOM
US100
US Tech 100
NASDAQ
GOOGL
Alphabet
COIN
ADAUSD
Cardano
FX
EURJPY
Euro vs Yen
TG
LHA
Deutsche Lufthansa
NYSE
XOM
Exxon Mobil
COIN
AVAXUSD
Avalanche
NYSE
MRK
Merck
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
ADDYY
Adidas (QX)
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten